IBRX - ImmunityBio, Inc. Stock Price, Fair Value and News

$2.62-0.05 (-1.87%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

IBRX Price Action

Last 7 days

-8.7%

Last 30 days

-46.3%

Last 90 days

-25.6%

Trailing 12 Months

-35.8%

IBRX RSI Chart

IBRX Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-3.11

Price/Sales (Trailing)

5.5K

EV/EBITDA

-3.81

Price/Free Cashflow

-4.21

IBRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

IBRX Fundamentals

IBRX Revenue

Revenue (TTM)

622.0K

Rev. Growth (Yr)

7.3K%

Rev. Growth (Qtr)

483.19%

IBRX Earnings

Earnings (TTM)

-587.5M

Earnings Growth (Yr)

10.31%

Earnings Growth (Qtr)

36.3%

IBRX Profitability

EBT Margin

-94520.90%

Return on Equity

78.95%

Return on Assets

-161.16%

Free Cashflow Yield

-23.78%

IBRX Investor Care

Shares Dilution (1Y)

4.36%

Diluted EPS (TTM)

-0.91

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	586.0K	592.0K	556.0K	622.0K
2022	760.5K	587.0K	413.5K	240.0K
2021	687.3K	769.5K	851.8K	934.0K
2020	2.4M	2.6M	2.8M	605.0K
2019	585.8K	1.1M	1.7M	2.2M
2018	2.0M	1.4M	701.5K	47.0K
2017	3.0M	2.9M	2.8M	2.7M
2016	3.0M	3.1M	3.1M	3.1M
2015	475.0K	384.0K	364.0K	3.0M
2014	610.3K	620.5K	630.8K	641.0K
2013	0	0	0	600.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company is based in San Diego, California.

CEO	Mr. Richard Gerald Adcock
WEBSITE	https://immunitybio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	683

ImmunityBio, Inc. Frequently Asked Questions

What is the ticker symbol for ImmunityBio, Inc.? What does IBRX stand for in stocks?

IBRX is the stock ticker symbol of ImmunityBio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ImmunityBio, Inc. (IBRX)?

As of Fri Dec 20 2024, market cap of ImmunityBio, Inc. is 1.83 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IBRX stock?

You can check IBRX's fair value in chart for subscribers.

Is ImmunityBio, Inc. a good stock to buy?

The fair value guage provides a quick view whether IBRX is over valued or under valued. Whether ImmunityBio, Inc. is cheap or expensive depends on the assumptions which impact ImmunityBio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IBRX.

What is ImmunityBio, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, IBRX's PE ratio (Price to Earnings) is -3.11 and Price to Sales (PS) ratio is 5.55 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IBRX PE ratio will change depending on the future growth rate expectations of investors.